1-Bromo-2-methoxy-3-nitro-benzene

1-Bromo-2-methoxy-3-nitro-benzene inoshandiswa sepakati peEltrombopag .
Eltrombopag, yakagadziridzwa naGlaxoSmithKline (GSK) kuUK uye yakazogadziriswa pamwe chete neNovartis kuSwitzerland, ndiyo yekutanga uye yakatenderwa chete mamorekuru madiki asiri peptide TPO receptor agonist munyika.Eltrombopag yakabvumidzwa neUS FDA muna 2008 kurapwa kweidiopathic thrombocytopenic purpura (ITP), uye muna 2014 kurapwa kweaplastic anemia (AA).Ndiwo zvakare mushonga wekutanga wakabvumidzwa neUS FDA kurapwa kweAA mumakore makumi matatu apfuura.
Muna Zvita 2012, US FDA yakabvumidza Eltrombopag kurapwa kwethrombocytopenia muvarwere vane chisingaperi hepatitis C (CHC), kuitira kuti varwere veHepatitis C vane hurombo husina kunaka nekuda kwekuderera kweplatelet count vanogona kutanga nekuchengetedza interferon based standard therapy yezvirwere zvechiropa.Musi waFebruary 3, 2014, GlaxoSmithKline yakazivisa kuti FDA yakapa mukana wekurapa mushonga weEltrombopag kurapwa kwehemopenia muvarwere vane yakanyanya chemicalbook aplastic anemia (SAA) vasina kupindura zvizere kune immunotherapy.Musi waNyamavhuvhu 24, 2015, US FDA yakabvumidza Eltrombopag kurapwa kwethrombocytopenia muvakuru nevana vane makore 1 uye kupfuura vane chronic immune thrombocytopenia (ITP) vasina mhinduro yakakwana kune corticosteroids, immunoglobulins kana splenectomy.Musi waJanuary4, 2018, Eltrombopag yakabvumidzwa kunyorwa muChina kurapwa kwekutanga immune thrombocytopenia (ITP).